Perioperative Management of Patients Taking Direct Oral Anticoagulant Medications
Aug 12, 2024
auto_awesome
James D. Douketis, MD, a specialist in anticoagulant management from McMaster University, teams up with Kristin L. Walter, MD, MS, a JAMA Deputy Editor with a focus on clinical research. Together, they dive into the nuances of managing direct oral anticoagulants (DOACs) during surgical procedures. They explore bleeding risks, the pharmacokinetics of DOACs, and tailored strategies for individual patient safety. The duo also discusses the emerging role of Dolex in perioperative care and stresses the need for healthcare professionals to stay informed.
DOACs require careful perioperative management to determine the optimal timing for discontinuation and resumption based on surgery type and bleeding risk.
In emergency surgical situations, protocols must be adapted based on urgency and the timing of the last DOAC dose to mitigate bleeding and thromboembolism risks.
Deep dives
Understanding Direct Oral Anticoagulants (DOACs)
Direct oral anticoagulants (DOACs) such as Apixaban, Dabigatran, Edoxaban, and Rivaroxaban are increasingly prescribed for conditions like atrial fibrillation and venous thromboembolism. These medications have specific pharmacokinetic properties, notably a half-life of about 10 to 12 hours, and a peak onset of action around two hours after administration. This quick action necessitates careful perioperative management, especially for patients scheduled for surgery, as clinicians must determine the appropriate timing for stopping or resuming these medications. Understanding the distinct differences between DOACs and traditional anticoagulants like warfarin is essential, particularly given the safety profile of DOACs, which tends to involve less bleeding and eliminates the need for routine blood monitoring.
Bleeding Risk Assessment and Management Strategies
The risk of bleeding during surgeries is categorized according to the type of procedure, which can significantly dictate how DOACs are managed. Procedures with minimal bleeding risk, like routine dental work, generally do not require discontinuation of DOACs, while those at high bleeding risk, such as major orthopedic or cardiac surgeries, necessitate a thorough interception of the anticoagulant beforehand. Effective perioperative planning includes guidelines for timing, where low to moderate risk procedures may involve ceasing DOACs two days prior, whereas high bleeding risk cases might require stopping the medication four days in advance. Additionally, patients undergoing endoscopic procedures may need individualized plans based on the specific nature of their procedure, highlighting the need for clear communication among healthcare providers.
Management of Urgent Surgical Situations
In emergencies requiring surgery for patients on DOACs, distinct protocols must be established based on the urgency and type of surgery. Emergency procedures should ideally occur within six to eight hours, while semi-urgent surgeries typically occur within 24 hours, with careful consideration of when the last dose of the DOAC was taken. Risks associated with bleeding and thromboembolism increase in these scenarios due to the patient's compromised condition, requiring multidisciplinary collaboration for effective management. Furthermore, the availability of DOAC reversal agents plays an essential role in decision-making, albeit with limitations in their accessibility and effectiveness that practitioners must navigate during urgent clinical interventions.
Direct oral anticoagulants (DOACs) are commonly used to treat patients with atrial fibrillation and venous thromboembolism. Author James D. Douketis, MD, from McMaster University discusses with JAMA Deputy Editor Kristin L. Walter, MD, MS, the management of DOACs in patients undergoing an elective or emergency surgery or procedure. Related Content:
